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controls, indicating that they are a specific pathology 
caused by mutant CHMP2B. Ultrastructural analysis and 
immuno-gold labelling confirmed that they are derived 
from the endolysosomal system. Consistent with these 
findings, CHMP2B mutation patient brains contain mor-
phologically similar autofluorescent aggregates. These 
aggregates occur significantly more frequently in human 
CHMP2B mutation brain than in neurodegenerative disease 
or age-matched control brains. These data suggest that lys-
osomal storage pathology is the major neuronal pathology 
in FTD caused by CHMP2B mutation. Recent evidence 
suggests that two other genes associated with FTD, GRN 
and TMEM106B are important for lysosomal function. 
Our identification of lysosomal storage pathology in FTD 
caused by CHMP2B mutation now provides evidence that 
endolysosomal dysfunction is a major degenerative path-
way in FTD.
Abstract Mutations in the charged multivesicular body 
protein 2B (CHMP2B) cause frontotemporal dementia 
(FTD). We report that mice which express FTD-causative 
mutant CHMP2B at physiological levels develop a novel 
lysosomal storage pathology characterised by large neu-
ronal autofluorescent aggregates. The aggregates are an 
early and progressive pathology that occur at 3 months 
of age and increase in both size and number over time. 
These autofluorescent aggregates are not observed in 
mice expressing wild-type CHMP2B, or in non-transgenic 
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Introduction
Frontotemporal dementia (FTD) is the second most com-
mon form of young-onset dementia [17, 32]. FTD is char-
acterised by atrophy of the frontal and temporal lobes, 
which results in alterations in personality, behaviour or 
language [26, 28]. FTD also shows clinical overlap with 
amyotrophic lateral sclerosis (ALS) and FTD and ALS 
share common pathologies and genetic causes [3].
Mutations in a number of genes are known to cause 
familial FTD. Mutations in the genes that encode tau 
(MAPT), progranulin (GRN) and C9orf72 are the most 
common causes of FTD, whilst rare mutations have been 
identified in valosin-containing protein (VCP), TDP-43 
(TARDBP), fused in sarcoma (FUS) and charged multi-
vesicular body protein 2B (CHMP2B) [33]. It is currently 
unclear how defects in such diverse genes result in specific 
degeneration of neurons of the frontal and temporal lobes.
A mutation in CHMP2B is responsible for an autoso-
mal dominant form of inherited FTD (termed FTD-3) in 
a Danish cohort [24, 35]. The mutation occurs in a splice 
acceptor site, resulting in the production of two variants of 
C-terminally truncated CHMP2B proteins: CHMP2BIntron5 
in which the final 36 amino acids are replaced with a single 
valine residue, or CHMP2B∆10 in which the final 36 amino 
acids are replaced with 29 nonsense residues [35]. A sub-
sequent study in a Belgian FTD cohort identified a familial 
FTD patient with a distinct truncation mutation CHMP-
2BQ165X that leads to the loss of the final 49 amino acids, 
providing further evidence that C-terminal truncations of 
CHMP2B lead to FTD [20, 41].
CHMP2B functions as a subunit of the endosomal 
sorting complex required for transport III (ESCRT-III). 
ESCRTs are multi-subunit complexes, highly conserved 
from yeast to mammals, which mediate the bending and 
fission of membranes [18]. Membrane manipulation by 
ESCRT complexes occurs through the sequential recruit-
ment of the multimeric complexes ESCRTS 0 through III, 
which function to scaffold membrane deformation, and 
finally recruit VPS4 to fission the deformed membranes. 
This process of membrane bending is used for several bio-
logically diverse but topologically similar processes: during 
the final stages of cell division, during virus egress from 
cells, and importantly for this study, during the maturation 
of endosomes [18]. Maturing endosomes acquire numerous 
intraluminal vesicles (ILVs) during their progress to late 
endosomes, which are also known as multivesicular bodies 
(MVBs). MVBs ultimately fuse with lysosomes to allow 
degradation of the endosomal content [18, 27]. In addition, 
MVBs fuse with autophagosomes to form hybrid com-
partments termed amphisomes, which then fuse with lys-
osomes, enabling degradation [5, 27]. Mutant CHMP2BIn-
tron5 has been shown to affect the maturation of both 
endosomes and autophagosomes [10, 22, 25, 38], impli-
cating impaired lysosomal degradation as a key pathway 
in FTD caused by CHMP2B mutation. Importantly, accu-
mulating evidence suggests that progranulin, a common 
genetic cause of FTD, and TMEM106B a major risk factor 
for FTD also have roles in endolysosomal function [7, 9, 
16, 21, 34, 36, 37], with progranulin mutations leading to 
pathology reminiscent of lysosomal storage disorders [16].
We have previously shown that transgenic mice express-
ing endogenous levels of human C-terminally truncated 
mutant CHMP2BIntron5 show progressive gliosis and p62 
inclusion pathology, which are also observed in CHMP2B 
mutation patient brain [14, 19]. Here we report, using 
immunoblotting and light and electron microscopy, that 
these CHMP2BIntron5 mice additionally develop a separate 
and distinct progressive lysosomal storage pathology that 
is characterised by large autofluorescent aggregates. These 
autofluorescent aggregates are not seen in CHMP2Bwild-type 
transgenics, or non-transgenic control mice. Importantly, 
we also report increased autofluorescent aggregates in the 
frontal cortex of FTD-3 patients with the CHMP2B muta-
tion, when compared to neurodegenerative disease controls. 
These data indicate that impaired lysosomal storage is a 
novel pathological pathway in the aetiology of FTD caused 
by CHMP2B mutation, and provide evidence that lysoso-
mal degradation is a key pathway in FTD pathogenesis.
Materials and methods
Mice
The mutant CHMP2BIntron5 expressing mouse line Tg153 
was used and maintained as a homozygous line as previously 
described [14]. The full-length human CHMP2BWild-type 
mouse line Tg168 was maintained as a hemizygous line 
and non-transgenic littermates used for controls as previ-
ously described [14].
Mouse brain immunofluorescence and pathology 
quantification
Mouse brains were immersion fixed in 10 % buffered for-
mal saline, embedded in paraffin wax and sections cut at 
3–4 μm thickness. Antigen retrieval was performed by 
microwaving for 20 min in 0.1 M citrate buffer. Primary 
antibodies were as follows: p62 (GP62-C, PROGEN), 
β-III tubulin (ab78078, Abcam), Iba1 (019-19741, Wako), 
Iba1 (ab5076, Abcam), GFAP (Z0334, DAKO), SMI-94 
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(Ab24567, Abcam) and CAII (ab6621, Abcam). Alexa 
Fluor-conjugated secondary antibodies (Life Technolo-
gies) were used to visualise the staining. Images were col-
lected using a 40× lens with 1.4 NA on a Zeiss LSM 710, 
or a 63× lens with a 1.4 NA on a Zeiss LSM 510 confo-
cal microscope. Spectral imaging with subsequent linear 
unmixing was used to separate the autofluorescence from 
the emission of each of the Alexa Fluor-labelled second-
ary antibodies. Quantification was performed blinded on 
three mice per genotype (CHMP2BIntron5, CHMP2BWild-type 
and non-transgenics) at 3, 6, 12 and 18 months of age. Six 
40× images were taken from the thalamus and cortex of 
each sample. Volocity software (Perkin-Elmer) was used to 
automatically identify fluorescent populations, with images 
individually thresholded to remove background noise. 
Blood vessels were a specific background autofluorescence 
that were also identified by this image analysis protocol 
(for example see asterisk in Fig. 1a). To control for this 
interference, the background number of autofluorescent 
items was set as the average number of autofluorescent 
items in non-transgenic mice at 3 months of age, and was 
subtracted from all autofluorescent item counts. Cellular 
localisation of autofluorescent items was determined man-
ually based on their presence within either Iba1- or β-III 
tubulin-positive cells. Statistical analysis was performed 
with Graphpad Prism 5 software, using either a two-way or 
a one-way ANOVA with post hoc Bonferroni tests analys-
ing selected pairs of columns, or a Student’s t test, as indi-
cated in the figure legends.
Cases
Brain specimens (described in Table 1) were obtained from 
the Queen Square Brain Bank for Neurological Disorders, 
UCL Institute of Neurology; the MRC London Neurode-
generative Diseases Brain Bank, Institute of Psychiatry, 
King’s College London; the Division of Neuropathol-
ogy, UCL Institute of Neurology, and the Frontotemporal 
Dementia Research in Jutland Association. Paraffin-embed-
ded frontal cortex sections (7 μm) were analysed for 
FTD-3 (n = 5), Alzheimer’s disease pathology (n = 3) and 
age-matched neurologically normal controls (n = 5). The 
study was approved by the UCL Institute of Neurology and 
National Hospital for Neurology and Neurosurgery Local 
Research Ethics Committee.
Human brain immunofluorescence and pathology 
quantification
Imaging was performed using standard confocal multi-
channel imaging, with autofluorescence identified by its 
presence in all channels. Immunofluorescence staining and 
autofluorescent object identification were performed as 
above for mouse sections. Quantification of pathology was 
performed on all cases by a researcher blinded to the sam-
ple origin. Autofluorescent objects were manually catego-
rised based on their characteristic morphology (see Figs. 7, 
S8), enabling differentiation of granular lipofuscin from the 
large, dense autofluorescent aggregates. Autofluorescent 
objects were localised to either microglia (identified by 
Iba1 positive staining), or neurons (identified by their char-
acteristic large nuclei).
Conventional electron microscopy
Mice aged to either 6 or 18 months were perfusion fixed 
with 4 % paraformaldehyde (PFA) and the brains removed 
and post-fixed overnight in the same fixative. 100 μm thick 
sections were cut using a vibratome. Areas of interest were 
dissected and refixed with 2 % PFA/2.5 % glutaraldehyde 
in 0.1 M cacodylate buffer. The tissue was then post-fixed 
with 1 % osmium tetroxide before being dehydrated with 
ethanol, and embedded in Araldite epoxy resin (Agar sci-
entific, UK).
Ultrathin sections (70 nm) were cut using a diamond 
knife mounted to a Reichert Ultracut S ultramicrotome 
(Leica, UK) and picked up onto coated EM grids. The sec-
tions were stained with lead citrate and observed in a FEI 
Tecnai Spirit (Eindhoven, Netherlands) transmission elec-
tron microscope at an operating voltage of 80 kV. In con-
ventional electron microscopy, neurons were identified by 
their characteristic large nuclei with a clear nucleolus and 
electron lucent cytoplasm, as observed in NeuN immuno-
gold-labelled cells. Oligodendrocytes were identified by 
their characteristic darker cytoplasm.
Pre‑embedding labelling of mouse brains for electron 
microscopy
Mouse brains were fixed and dissected as described above. 
Thick sections were washed with HEPES buffered saline 
(HBS) pH 7.4 before being permeabilised in HBS con-
taining 0.05 % Triton x-100 and 10 % BSA. Tissue was 
incubated with primary antibodies overnight at 4 °C in 
HBS with 0.005 % Triton x-100 and 1 % BSA. Primary 
antibodies used were as follows: LAMP1 (1D4B, Univer-
sity of Iowa Hybridoma Bank), LAMP2 (Abl-93, Univer-
sity of Iowa Hybridoma Bank), p62 (GP62-C, PROGEN), 
β-III tubulin (D71G9, cell signalling), NeuN (ABN78, Mil-
lipore), GFAP (Z0334, Dako) and Iba1 (ab5076, Abcam). 
Tissue was then washed before being incubated with either 
anti-mouse or anti-rabbit nanogold secondaries (Nano-
probes, USA). The tissue was washed before being refixed 
with 2 % PFA/2.5 % glutaraldehyde in 0.1 M cacodylate 
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Fig. 1  Progressive accumulation of autofluorescent aggregates in 
CHMP2BIntron5 mice. a Spectrally unmixed images showing auto-
fluorescent aggregates in the thalamus of CHMP2BIntron5 mice, but 
not in CHMP2BWild-type or non-transgenic control samples at 3, 6, 12 
or 18 months of age. Nuclei are stained with DAPI (blue), neurons 
with β-III tubulin (magenta) and autofluorescence is shown in cyan. 
Arrows indicate autofluorescent aggregates, arrowheads indicate lipo-
fuscin and an asterisk indicates a blood vessel. Scale bar 20 μm. b 
Quantification of the number of autofluorescent items in the thala-
mus of CHMP2BIntron5, CHMP2BWild-type and non-transgenic con-
trol mice. c Average size of neuronal autofluorescent items at 3, 6, 
12 and 18 months in the thalamus of CHMP2BIntron5 mice. Data are 
shown as mean ± SEM. Significance was determined using a two-
way ANOVA, with post hoc Bonferroni test. *p < 0.05, **p < 0.01, 
***p < 0.001. All statistically significant differences are shown
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buffer. Nanogold particles were then enhanced using Gold-
enhance (Nanoprobes, USA). Tissue was then post-fixed 
with 1 % osmium tetroxide and processed for resin embed-
ding as described above.
Immunoblotting
The olfactory bulb and cerebellum were removed from 
whole brains, and homogenates prepared from the remain-
der in Dulbecco’s phosphate-buffered saline containing 
complete EDTA-free protease inhibitors (Roche) using a 
TissueRuptor (Qiagen) to make a 10 % w/v solution. Fol-
lowing a 2-min 200×g spin to pellet debris, the supernatant 
was combined 1:1 with 2 % sarkosyl (N-lauroylsarcosine) 
in D-PBS. Benzonase (Novagen) was added to digest DNA 
and the homogenates were incubated with constant agita-
tion at 37 °C for 1 h. 2× Laemmli sample buffer was added 
and the samples were heated at 100 °C for 10 min prior to 
sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
Samples were run on 4–12 % or 10 % Bis’-Tris gels (Life 
Technologies) with MOPS buffer, then transferred onto poly-
vinylidene fluoride, blocked with 5 % bovine serum albumin 
in PBS-T, and probed using either anti-LAMP-1 (1D4B, 
University of Iowa) or anti-cathepsin-D (sc-6486, Santa 
Cruz Biotechnology), respectively. Loading controls were 
performed using mouse anti-β-actin (A5441, Sigma). Detec-
tion was performed with horseradish peroxidase-conjugated 
secondary antibodies and SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Scientific). Quantification was 
performed using ImageJ software. Band intensity was nor-
malised to the indicated loading control, and averages taken 
of three mice per genotype.
Results
Autofluorescent aggregates are a specific 
and progressive pathology in CHMP2BIntron5 mice
We observed that CHMP2BIntron5 mice developed autofluo-
rescent aggregates that fluoresce at all spectra of excitation/
emission. Lambda imaging and spectral unmixing were 
used to identify all autofluorescent objects in brain sections 
from CHMP2BIntron5, CHMP2Bwild-type, or non-transgenic 
mice, in combination with β-III tubulin staining to iden-
tify neurons at 3, 6, 12 or 18 months of age. We focused on 
the thalamus (Fig. 1a) and cortex (Fig. S1) as these are the 
main sites of pathology in CHMP2BIntron5 mice [14]. We 
noted two morphologically distinct types of autofluorescent 
material in neurons: (i) age-related lipofuscin depositions, 
which are present in all mice and have a granular dot-like 
appearance (arrowheads in Fig. 1a); and (ii) large, dense 
aggregates which are only present in CHMP2BIntron5 mice 
(arrows in Fig. 1a). We next performed automated analysis 
of the number of autofluorescent items. Our automated 
analysis removed the smallest autofluorescent items using 
a size cutoff but was not able to effectively distinguish 
between the large dense autofluorescent aggregates and 
lipofuscin, due to the clumping of the lipofuscin dots. 
Therefore, lipofuscin deposits were also counted and as 
expected accumulated in non-transgenic and CHMP2Bwild-
type mice by 18 months of age (Fig. 1b). Due to the addi-
tional presence of the large autofluorescent aggregates, 
CHMP2BIntron5 mice had higher numbers of autofluorescent 
items at all ages (Fig. 1b). This was confirmed by plotting 
the size distribution of all detected autofluorescent items, 
which showed that as CHMP2BIntron5 mice increase in age, 
they had a significantly greater proportion of larger auto-
fluorescent items than non-transgenic and CHMP2Bwild-type 
mice, even with the limitation that large lipofuscin clumps 
common to all genotypes were also counted (Fig. S2). Fur-
ther quantification showed that the CHMP2BIntron5 autoflu-
orescent aggregates increase in size and frequency with age 
(Fig. 1b, c).
Autofluorescent aggregates are distinct from p62 
inclusions in CHMP2BIntron5 mice
To assess the relationship between this autofluorescent 
pathology and the p62 inclusions we have previously 
reported in CHMP2BIntron5 mice [14], we analysed their 
co-occurrence in the thalamus (Fig. 2) and the cortex 
(Fig. S3). Both types of pathology were found to occur 
frequently in the cortex and thalamus of CHMP2BIntron5 
Table 1  Details of cases used in this study
Diagnosis Sex Age at death Postmortem interval
Control M 71 5
Control M 61 53
Control F 68 9
Control M 57 79
Control F 68 45
AD M 79 96
AD F 65 30
AD F 79 38
FTD-3 F 61 Unknown
FTD-3 F 76 Unknown
FTD-3 M 54 30
FTD-3 F 87 18
FTD-3 F 69 18
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mice, but without obvious overlap in localisation. This 
clearly indicates that the p62 inclusions and autofluores-
cent aggregates are distinct pathologies. However, in addi-
tion to the discrete p62 inclusions, occasionally autofluo-
rescent aggregates could be detected that were surrounded 
by a halo of p62 (for example see Fig. S3, arrow in upper 
inset), which may indicate an attempt to target the aggre-
gates for degradation.
CHMP2BIntron5 autofluorescent aggregates occur 
in neurons and microglia
We next determined the cellular localisation of CHMP2BIn-
tron5 autofluorescent aggregates using cell-type specific 
markers. Autofluorescent aggregates were found to pre-
dominantly localise to either neurons or microglia (Fig. 3a) 
but not to astrocytes (Fig. S4). This is in contrast to the 
localisation of p62 inclusions, which we found to be pre-
dominantly localised to oligodendrocytic processes (Fig. 
S5), but not neurons, astrocytes or microglia (Figs. 2, S4, 
S6). Oligodendrocyte localisation was consistent with the 
prominent association of p62 inclusions with axonal tracts, 
such as those in the white matter of the corpus callosum 
(Fig. S7). The presence of p62 inclusions and autofluores-
cent aggregates in different cell types further confirmed that 
they are distinct pathologies. By 18 months, approximately 
half of the neurons in the cortex contained autofluorescent 
aggregates (49.3 ± 5.8 %, Fig. 3b). In the thalamus, an 
even greater proportion of neurons contained autofluores-
cent aggregates (61.9 ± 4.9 %). Microglia also had a very 
high burden of autofluorescent pathology: 89.8 ± 6.9 % in 
the cortex, and 89.8 ± 9.3 % in the thalamus, at 18 months 
of age. In the thalamus, at 18 months, the autofluorescent 
microglial aggregates were significantly larger than the 
neuronal aggregates, by approximately threefold (Fig. 3c). 
A similar but non-significant trend towards larger micro-
glial aggregates was also observed in the 18-month cortex. 
These data show that autofluorescent aggregates are found 
extensively in microglia and neurons and are the major 
neuronal pathology in CHMP2BIntron5 mice.
CHMP2BIntron5 neuronal aggregates are 
membrane‑bound and associated with the 
endolysosomal system
To determine the ultrastructure of deposits in CHMP2BIn-
tron5 mice, conventional electron microscopy (EM) was 
performed on the cortex and thalamus of 18-month-old 
CHMP2BIntron5 and non-transgenic mice. Consistent 
with our light microscopy data, CHMP2BIntron5 mice dis-
played numerous large aggregates within neurons (aster-
isks, Fig. 4), whilst smaller and less frequent lipofus-
cin-like deposits were observed in non-transgenic mice 
(average areas: CHMP2BIntron5 3.99 ± 3.33 μm2, n = 38 
Fig. 2  Autofluorescent aggregates and p62-positive inclusions are 
distinct pathologies. Spectrally unmixed images of p62 staining (red) 
and autofluorescence (white) in the thalamus of 12- and 18-month-old 
CHMP2BIntron5 mice shows little overlap between p62 and autofluo-
rescence. Neurons are stained with β-III tubulin (green), and nuclei 
with DAPI (blue). Scale bar 10 μm
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deposits; non-transgenic 0.77 ± 0.42 μm2, n = 35 deposits, 
mean ± SD). CHMP2BIntron5 aggregates occasionally con-
tained lipid droplets (Fig. 4b). Interestingly, the CHMP2BIn-
tron5 aggregates were single membrane-bound (arrowheads 
Fig. 4a, b) and were often in close association with late 
endosomal/lysosomal structures such as multivesicular bod-
ies (inset in Fig. 4c) and compartments containing character-
istic membrane whorls (inset in Fig. 4d). To determine the 
precise nature of the membrane surrounding aggregates in 
CHMP2BIntron5 mouse brains, we performed pre-embedding 
labelling electron microscopy. Conventional EM analysis 
suggested that aggregates were of an endocytic origin, so 
the late endosome/lysosome markers LAMP-1 and LAMP-2 
were tested. Both epitopes were found to be present on the 
membranes surrounding neuronal aggregates (Fig. 5a–d). 
Membrane-bound compartments containing aggregated 
material were much larger than normal LAMP1/2 organelles. 
The neuronal aggregates were negative for p62 labelling 
(Fig. 5e), although some p62 membrane staining could be 
observed on small aggregates in oligodendrocytes (Fig. 5f), 
consistent with our light microscopy data (Figs. 2, S5). The 
ultrastructural examination of the large neuronal inclusions 
indicates that they are derived from the deposition and build-
up of lysosomal components, as is characteristically seen in 
lysosomal storage disorders which typically present with an 
accumulation of autofluorescent material [31]. 
Accumulation of lysosomal proteins in the brains 
of CHMP2BIntron5 mice
Our data are suggestive of a lysosomal storage-type 
pathology characterised by autofluorescent aggregates 
in CHMP2BIntron5 mice, so we next investigated whether 
components of the lysosome were accumulating in brains 
from these mice. A significant accumulation of the lyso-
somal proteins LAMP-1 and cathepsin D was observed 
at 18 months of age in the brains of CHMP2BIntron5 mice 
compared to non-transgenic controls (Fig. 6). This indi-
cates that FTD caused by CHMP2B mutation recapitulates 
aspects of lysosomal storage disorder pathology.
Fig. 3  Autofluorescent aggregates are found in neurons and micro-
glia in CHMP2BIntron5 mice. a Cell-type specific staining in the thala-
mus of 18-month-old CHMP2BIntron5 brain shows that autofluorescent 
aggregates (cyan) can be localised to neurons (β-III tubulin—red) or 
microglia (Iba1—green). Nuclei are stained with DAPI (blue). The 
dotted boxes in the merged image are enlarged in the panel below. 
Scale bar 10 μm. b Quantification of the percentage of neurons or 
microglia containing autofluorescent aggregates in the cortex and the 
thalamus of 18-month CHMP2BIntron5 mice. c Quantification of the 
size of perinuclear autofluorescent aggregates in neurons or microglia 
from the cortex and the thalamus of 18-month CHMP2BIntron5 mice. 
Data are shown as mean ± SEM. Significance was determined using 
a Student’s t test. ***p < 0.001. All statistically significant differences 
are shown
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Autofluorescent aggregates accumulate abnormally 
and selectively in the cortex of FTD‑3 patients
To assess the relevance of the autofluorescent aggre-
gates found in CHMP2BIntron5 mice to human FTD-3 with 
CHMP2B mutation, we investigated the occurrence of 
autofluorescence in the frontal cortex of FTD-3 patient tis-
sue. To assess specificity, we also examined tissue from 
brains with Alzheimer’s disease pathology, as a neurode-
generative disease control, and neurologically normal age-
matched control samples (Table 1). As our analysis soft-
ware was unable to distinguish between lipofuscin and the 
autofluorescent aggregates, a researcher blinded to sample 
origin separated each autofluorescent item identified by 
the software into distinct categories based on their distinc-
tive morphology: large, dense autofluorescent aggregates 
or the more granular lipofuscin (Figs. 7a, S8). The tissue 
coverage of autofluorescent aggregates in frontal cortex 
was highest in FTD-3 and significantly greater than both 
neurologically normal and Alzheimer’s disease (AD) con-
trols (Fig. 7b). Cell-type specificity was also analysed in 
the patient tissue. The percentage of neurons containing 
autofluorescent aggregates was also significantly higher in 
FTD-3 cases versus controls (Fig. 7c). Extensive lipofus-
cin was prevalent in all samples, as expected of aged brain 
tissue (Fig. 7b, d). Autofluorescent aggregates were not 
detected in neurologically normal control neurons, suggest-
ing that our morphological analysis was able to distinguish 
this novel autofluorescent pathology from age-related lipo-
fuscin autofluorescence. Although no significant difference 
was seen in the total coverage of autofluorescent aggregates 
between AD and controls (Fig. 7b), the percentage of neu-
rons containing autofluorescent aggregates in AD cases was 
significantly greater (Fig. 7c), indicating that AD neurons 
contain small autofluorescent aggregates. This is consistent 
with suggestions that endolysosomal dysfunction occurs 
in the pathogenesis of AD [30]. We further analysed the 
hippocampus which does not show extensive degenera-
tion in FTD-3, and did not observe large autofluorescent 
aggregates (Fig. S8). The occurrence of autofluorescent 
aggregates in FTD-3 CHMP2B mutation frontal cortex, 
combined with their early and progressive accumulation in 
Fig. 4  CHMP2BIntron5 mouse brains display large intraneuronal 
deposits. 18-month CHMP2BIntron5 mouse brains were prepared for 
conventional EM. Four examples of large deposits are shown (aster-
isks a–d), located next to large neuronal nuclei (Nu). These deposits 
were often single membrane-bound (arrowheads) and occasionally 
contained features suggestive of endocytic origin, such as multive-
sicular bodies (c inset) or lamellar membrane whorls typical of late 
endosome/lysosomes (d inset). Scale bars 1 μm
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CHMP2BIntron5 mice indicates that the build-up of lysoso-
mally derived material is a characteristic pathology of this 
disease.
Discussion
We have shown that in addition to p62 inclusions, the 
CHMP2BIntron5 mouse model of FTD exhibits a progressive 
autofluorescent aggregate pathology that is distinct from 
normal lipofuscin autofluorescence associated with age-
ing. These autofluorescent aggregates occur in neurons of 
the cortex and thalamus from 3 months of age. Aggregates 
increase in size and number over time, and by 18 months 
approximately half of neurons contain an autofluorescent 
aggregate. Our data clearly demonstrate that these auto-
fluorescent aggregates are the major neuronal pathology in 
CHMP2BIntron5 mice, as the p62-positive inclusions are not 
generally observed in neurons. Whilst little colocalisation 
was seen between the previously described p62 inclusions 
and the autofluorescent aggregates, occasionally a halo of 
p62 staining could be seen surrounding the autofluorescent 
aggregates. This may indicate p62 deposition on the lim-
iting membrane of the inclusion, signalling an attempt by 
the cell to label the inclusion for degradation. Similarly, the 
marked gliosis which we have previously reported in these 
Fig. 5  Intraneuronal deposits 
are of endolysosomal origin. 
18-month CHMP2BIntron5 
mouse brains were prepared 
for pre-embedding immuno-
EM. Neuronal deposits stained 
positively for LAMP-1 (a, b) 
or LAMP-2 (c, d), but not for 
p62 (e), although p62-positive 
structures could be observed 
in oligodendrocytes (f). Nu 
nucleus. Scale bars 1 μm
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mice [14] may indicate an attempt by microglia to clear 
neurons which have acquired a large burden of autofluores-
cent pathology. In agreement with this possibility, nearly 
all microglia in 18-month-old CHMP2BIntron5 mice contain 
autofluorescent aggregates, which are significantly larger in 
size than those found in neurons.
Ultrastructural analysis of the autofluorescent aggregates 
indicates that they are endosomal in origin, as they contain 
elements of multivesicular bodies and membrane whorls 
characteristic of late endosomal–lysosomal compart-
ments. Immunoblotting also confirmed the accumulation 
of endolysosomal proteins in 18-month-old CHMP2BIn-
tron5 mice. FTD-causing C-terminal truncation mutants of 
CHMP2B have been modelled in several systems, and have 
been found to cause perturbations in the endolysosomal 
and autophagy systems. Overexpression of CHMP2BIntron5, 
CHMP2B∆10 or CHMP2BQ165X in human neuroblastoma 
cells results in a characteristic enlarged endosomal pheno-
type [38, 41], which is also observed in both FTD-3 and 
CHMP2BQ165X patient fibroblasts [29, 38] and FTD-patient 
brain [38]. Overexpression of CHMP2BIntron5 in HeLa cells 
or primary cortical neurons leads to an accumulation of 
autophagosomes [10, 22], which may be due to ESCRT-III 
having a role in the closure of autophagosome membranes 
[25]. However, we did not observe an obvious increase in 
double membrane autophagosome structures by electron 
microscopy in CHMP2BIntron5 mouse brain, arguing against 
this being the primary effect of CHMP2BIntron5. In a sepa-
rate study, neither enlarged endosomes nor autophagosome 
accumulation were observed when CHMP2BIntron5 or 
CHMP2B∆10 was expressed in primary hippocampal neu-
rons [2]. We have now analysed the effect of expression of 
a physiologically relevant level of mutant CHMP2B on the 
neuronal endolysosomal system in vivo, and show that this 
results in an accumulation of autofluorescent endolysoso-
mally derived deposits.
Crucially, similar autofluorescent aggregates can also 
be detected in the brain of patients with FTD-3, indicating 
that accumulation of endolysosomally derived intermedi-
ates is a hallmark of FTD caused by mutation in CHMP2B. 
FTD-3 patients were found to have a significantly greater 
coverage of autofluorescent aggregates compared to age-
matched and neurodegenerative disease controls. The auto-
fluorescent aggregates in both CHMP2BIntron5 mice and 
FTD-3 patient brain were morphologically distinct from 
lipofuscin associated with normal ageing, which is also 
autofluorescent and lysosomally derived. Interestingly, a 
concomitant decrease was seen in the lipofuscin coverage 
in FTD-3 patients. This could be due to an exacerbation 
of the natural process of age-related lipofuscinosis lead-
ing to the much larger and denser deposits that we identify 
as autofluorescent aggregates. Another possibility is that 
CHMP2BIntron5-induced autofluorescent aggregate forma-
tion and lipofuscin formation are distinct processes that 
compete for lysosomal components. We have previously 
reported the presence of p62-positive inclusions in FTD-3 
patient brain, which predominantly occur in the hippocam-
pus and are rare in the frontal cortex [19]. In contrast, the 
Fig. 6  Accumulation of lysosomal proteins in CHMP2BIntron5 
mouse brain. 18-month-old CHMP2BIntron5 mouse brain homogen-
ates were immunoblotted for components of the lysosome known to 
accumulate in lysosomal storage disorders. a LAMP-1 and b cathep-
sin D were both found to be elevated in aged CHMP2BIntron5 mouse 
brains compared to non-transgenic controls (c). Data are shown as 
mean ± SEM. Significance was determined using a Student’s t test. 
*p < 0.05. Actin blots confirm equal loading
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autofluorescent pathology was present in the frontal cor-
tex and rare/absent in the hippocampus, indicating the two 
pathologies rarely co-occur. As FTD-3 brains exhibit gross 
atrophy of the frontal cortex with no neurodegeneration in 
the hippocampus [19], the autofluorescent lysosomal stor-
age pathology, rather than the p62 inclusions, correlates 
best with neurodegeneration in FTD-3.
This is not the first evidence of a lysosomal pathology 
in FTD. Studies on mutations in GRN, the gene encoding 
progranulin, have already suggested a phenotypic over-
lap between FTD and lysosomal storage disorders. A pair 
of siblings suffering from neuronal ceroid lipofuscinosis 
(NCL) was found to have a homozygous mutation in GRN 
[36], and the same GRN mutation in the heterozygous state 
is known to cause FTD [4]. Close examination of Grn-defi-
cient mice has revealed that these mice recapitulate features 
of both FTD and NCL: aged Grn knockout mice display 
an accumulation of proteins which are characteristically 
seen in NCL [16], and also display increased lipofuscin [1]. 
However, as lipofuscin and the autofluorescent aggregates 
we observe in CHMP2BIntron5 mice are morphologically 
distinct, it is not clear whether a common upstream patho-
genic pathway is shared or whether distinct neurodegen-
erative pathways converge on the lysosome. In addition to 
these mouse studies, FTD–GRN patients were also found 
to have elevated levels of characteristic NCL storage com-
ponents [16]. Interestingly, TMEM106B, a well-replicated 
risk factor for FTD [11, 12, 39, 40, 42], is localised to the 
lysosome [7, 9, 21], and has been implicated in the neu-
ronal trafficking of endolysosomal structures [34, 37]. Our 
finding that FTD caused by CHMP2B mutation is charac-
terised by neuronal lysosomal storage pathology now pro-
vides evidence that endolysosomal dysfunction is major 
pathway in the aetiology of FTD.
Whilst the accumulating evidence that lysosomal dys-
function is a major pathway in FTD indicates that it is 
likely to be an important neurodegenerative pathway medi-
ated by CHMP2BIntron5, it does not rule out a role for other 
Fig. 7  Autofluorescent aggregates are a characteristic pathology of 
FTD-3 patient brain. Autofluorescent pathology in frontal cortex tis-
sue from FTD-3, AD and neurologically normal control brains was 
investigated. a Examples of an autofluorescent aggregate in FTD-3 
patient frontal cortex, and the morphologically distinct granular lipo-
fuscin in control cortex. DAPI labels the nuclei (blue). b Blinded 
quantification of the coverage of autofluorescent aggregates or lipo-
fuscin per field of view in control, AD or FTD-3 patient frontal cor-
tex. Percentage of either neurons or microglia containing autofluo-
rescence (c) or lipofuscin (d). Data are shown as individual symbols 
per case with bars representing mean ± SEM. Closed symbols auto-
fluorescent aggregates, open symbols lipofuscin. Significance was 
determined using a one-way ANOVA, with post hoc Bonferroni test. 
*p < 0.05, **p < 0.01, ***p < 0.001. All statistically significant dif-
ferences are shown
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mechanisms, such as an effect on dendritic spine mainte-
nance and function, which have also been reported [2, 6, 
8]. In addition, multivesicular bodies, late endosomes and 
specifically ESCRTs have also been shown to play a role 
in the life cycle of microRNAs [15, 23], and it was recently 
reported that microRNA-124 is decreased in another 
CHMP2BIntron5 mouse model, leading to an alteration in 
AMPA receptor composition, which may also contribute to 
aspects of the disease phenotype [13].
We have shown here that mutant CHMP2B causes the 
pathological accumulation of endolysosomal components 
early in the disease course. Why defects in the endolysoso-
mal system specifically lead to degeneration of the subset 
of neurons that are lost in FTD-3 is unclear. Cortical neu-
rons may be particularly sensitive to perturbations in the 
endolysosomal equilibrium, such as alterations in endolys-
osomal trafficking in axons and dendrites. The CHMP2B 
mutation will be a powerful tool for investigating pertur-
bations in neuronal endolysosomal dynamics and may pro-
vide insight into the earliest events occurring in the devel-
opment of FTD.
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